These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 36351720)

  • 1. Reirradiation Options for Previously Irradiated Prostate cancer (RO-PIP): Feasibility study investigating toxicity outcomes following reirradiation with stereotactic body radiotherapy (SBRT) versus high-dose-rate brachytherapy (HDR-BT).
    Zhong J; Brown S; Serra M; Shuttleworth P; Bownes P; Thompson C; Reed R; Reeves K; Dubec M; McHugh D; Eccles C; Chuter R; Tsang YM; Taylor NJ; West C; Buckley D; Scarsbrook A; Choudhury A; Hoskin P; Henry A
    BMJ Open; 2022 Nov; 12(11):e068580. PubMed ID: 36351720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER).
    Valle LF; Lehrer EJ; Markovic D; Elashoff D; Levin-Epstein R; Karnes RJ; Reiter RE; Rettig M; Calais J; Nickols NG; Dess RT; Spratt DE; Steinberg ML; Nguyen PL; Davis BJ; Zaorsky NG; Kishan AU
    Eur Urol; 2021 Sep; 80(3):280-292. PubMed ID: 33309278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage Reirradiation Options for Locally Recurrent Prostate Cancer: A Systematic Review.
    Zhong J; Slevin F; Scarsbrook AF; Serra M; Choudhury A; Hoskin PJ; Brown S; Henry AM
    Front Oncol; 2021; 11():681448. PubMed ID: 34568012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brachytherapy boost (BT-boost) or stereotactic body radiation therapy boost (SBRT-boost) for high-risk prostate cancer (HR-PCa).
    Peyraga G; Lizee T; Khalifa J; Blais E; Mauriange-Turpin G; Supiot S; Krhili S; Tremolieres P; Graff-Cailleaud P
    Cancer Radiother; 2021 Jun; 25(4):400-409. PubMed ID: 33478838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy.
    Mbeutcha A; Chauveinc L; Bondiau PY; Chand ME; Durand M; Chevallier D; Amiel J; Kee DL; Hannoun-Lévi JM
    Radiat Oncol; 2017 Mar; 12(1):49. PubMed ID: 28274241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linac-based stereotactic salvage reirradiation for intraprostatic prostate cancer recurrence: toxicity and outcomes.
    Cozzi S; Finocchi Ghersi S; Bardoscia L; Najafi M; Blandino G; Alì E; Augugliaro M; Vigo F; Ruggieri MP; Cardano R; Giaccherini L; Iori F; Botti A; Trojani V; Ciammella P; Iotti C
    Strahlenther Onkol; 2023 Jun; 199(6):554-564. PubMed ID: 36732443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosimetry analyses comparing high-dose-rate brachytherapy, administered as monotherapy for localized prostate cancer, with stereotactic body radiation therapy simulated using CyberKnife.
    Fukuda S; Seo Y; Shiomi H; Yamada Y; Ogata T; Morimoto M; Konishi K; Yoshioka Y; Ogawa K
    J Radiat Res; 2014 Nov; 55(6):1114-21. PubMed ID: 24957754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of HDR brachytherapy-replicating prostate radiotherapy planning for tomotherapy, cyberknife and VMAT.
    de Chavez R; Grogan G; Hug B; Howe K; Grigg A; Waterhouse D; Lane J; Glyde A; Brown E; Bydder S; Pryor D; Hargrave C; Charles PH; Hellyer J; Ebert MA
    Med Dosim; 2022 Spring; 47(1):61-69. PubMed ID: 34551879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients.
    Levin-Epstein R; Cook RR; Wong JK; Stock RG; Jeffrey Demanes D; Collins SP; Aghdam N; Suy S; Mantz C; Katz AJ; Nickols NG; Miszczyk L; Napieralska A; Namysl-Kaletka A; Prionas ND; Bagshaw H; Buyyounouski MK; Cao M; Mahal BA; Shabsovich D; Dang A; Yuan Y; Rettig MB; Chang AJ; Jackson WC; Spratt DE; Lehrer EJ; Zaorsky NG; Kupelian PA; Steinberg ML; Horwitz EM; Jiang NY; Kishan AU
    Radiother Oncol; 2020 Oct; 151():26-32. PubMed ID: 32663537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. F-SHARP: a Phase I/II trial of focal salvage high-dose-rate brachytherapy for Radiorecurrent prostate cancer.
    Solanki AA; Yoo RK; Adams W; Davicioni E; Mysz ML; Shea S; Gupta GN; Showalter T; Garant A; Hentz C; Farooq A; Baldea K; Small W; Harkenrider MM
    BJU Int; 2024 Feb; 133(2):188-196. PubMed ID: 37562825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
    Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic Body Radiation Therapy and High-Dose-Rate Brachytherapy Boost in Combination With Intensity Modulated Radiation Therapy for Localized Prostate Cancer: A Single-Institution Propensity Score Matched Analysis.
    Chen WC; Li Y; Lazar A; Altun A; Descovich M; Nano T; Ziemer B; Sudhyadhom A; Cunha A; Thomas H; Gottschalk A; Hsu IC; Roach M
    Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):429-437. PubMed ID: 33385496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is robotic arm stereotactic body radiation therapy “virtual high dose ratebrachytherapy” for prostate cancer? An analysis of comparative effectiveness using published data [corrected].
    Zaorsky NG; Hurwitz MD; Dicker AP; Showalter TN; Den RB
    Expert Rev Med Devices; 2015 May; 12(3):317-27. PubMed ID: 25540018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response.
    Jabbari S; Weinberg VK; Kaprealian T; Hsu IC; Ma L; Chuang C; Descovich M; Shiao S; Shinohara K; Roach M; Gottschalk AR
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):228-34. PubMed ID: 21183287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage brachytherapy for locally-recurrent prostate cancer after radiation therapy: A comparison of efficacy and toxicity outcomes with high-dose rate and low-dose rate brachytherapy.
    Henríquez López I; González-San Segundo C; Vegas JO; Gutierrez C; Hervas A; Cabeza Rodriguez MÁ; Valero Albarrán J; Rodríguez Villalba S; Álvarez Gonzalez A; Sancho Pardo G; Zapatero A; Álvaro PC
    Radiother Oncol; 2019 Dec; 141():156-163. PubMed ID: 31570236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage reirradiation for local prostate cancer recurrence after radiation therapy. For who? When? How?
    Baty M; Créhange G; Pasquier D; Palard X; Deleuze A; Gnep K; Key S; Beuzit L; Castelli J; de Crevoisier R
    Cancer Radiother; 2019 Oct; 23(6-7):541-558. PubMed ID: 31421999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Safety and Efficacy of Salvage Stereotactic Radiation Therapy in Patients with Intraprostatic Tumor Recurrence After Previous External Radiation Therapy: Phase 1 Results from the GETUG-AFU 31 Study.
    Pasquier D; Lacornerie T; Supiot S; Pommier P; Quivrin M; Simon JM; Loos G; Meyer E; Calais G; Peiffert D; Vandendorpe B; Aymes E; Leguillette C; Brihoum M; Nenan S; Cormier L; Le Deley MC; Lartigau EF
    Eur Urol Oncol; 2023 Aug; 6(4):399-405. PubMed ID: 36754722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interim Results of a Prospective Prostate-Specific Membrane Antigen-Directed Focal Stereotactic Reirradiation Trial for Locally Recurrent Prostate Cancer.
    Bergamin S; Eade T; Kneebone A; Booth J; Hsiao E; Schembri GP; Szymura K; Le A; Kwong C; Brown C; Hunter J; Hruby G
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1172-1178. PubMed ID: 32659332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how?
    Créhange G; Roach M; Martin E; Cormier L; Peiffert D; Cochet A; Chapet O; Supiot S; Cosset JM; Bolla M; Chung HT
    Cancer Radiother; 2014 Oct; 18(5-6):524-34. PubMed ID: 25192626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review and recommendations for re-irradiation for intraprostatic radiorecurrent prostate cancer after definitive radiation therapy.
    Saripalli AL; Venkatesulu BP; Nickols NG; Valle LF; Harkenrider MM; Kishan AU; Solanki AA
    World J Urol; 2024 Sep; 42(1):520. PubMed ID: 39264453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.